Person: ERSÖZ, CEVPER
Search Results
Systematic versus cognitive targeted biopsy: evaluation of parameters related to clinically significant prostate cancer and comparison of detection rates
2022-10-01, Ersöz C., İlktaç A., Kalkan S., Kayalı Y., Akbulut H., Toprak H., Doğan B., ERSÖZ, CEVPER, İLKTAÇ, ABDULLAH, KALKAN, SENAD, AKBULUT, HABİB, TOPRAK, HÜSEYİN, DOĞAN, BAYRAM
CD47 expression in urothelial carcinoma and its correlation with histopathological findings.
2023-11-30, Çoban G., Yıldız P., Şahin N., Ersöz C., Toprak A., Ünver N., Elagöz Ş., ÇOBAN, GANİME, ŞAHİN, NURHAN, ERSÖZ, CEVPER
The Success of Pyeloplasty in Adult Patients with Ureteropelvic Junction Obstruction
2022-12-01, İLKTAÇ A., ERSÖZ C., DOĞAN B., AKBULUT H., İLBEY Y. Ö., İLKTAÇ, ABDULLAH, ERSÖZ, CEVPER, DOĞAN, BAYRAM, AKBULUT, HABİB, İLBEY, YUSUF ÖZLEM
Characteristics of the Patients Aged Less than 40 Years Operated for a Renal Mass.
2023-12-21, Ilktac A., Dogan B., Ersoz C., Coban G., Kalkan S., ERSÖZ, CEVPER, ÇOBAN, GANİME
PSA change after antibiotic treatment should not affect decision-making on performing a prostate biopsy
2023-02-01, Kayalı Y., Balbay M. D., İlktaç A., Ersöz C., Toprak H., Tarım K., Baygül A., Akçay M., Doğan B., İLKTAÇ, ABDULLAH, ERSÖZ, CEVPER, TOPRAK, HÜSEYİN, AKÇAY, MUZAFFER, DOĞAN, BAYRAM
The role of oxidative stress and inflammation biomarkers in pre- and postoperative monitoring of prostate cancer patients
2024-02-23, Beyaztas H., ERSÖZ C., Ozkan B. N., OLĞUN İ., Polat H. S., Dastan A. I., Cetinkaya E., Guler E. M., ERSÖZ, CEVPER, OLĞUN, İBRAHİM, GÜLER, ERAY METİN
Introduction: Prostate Cancer (PC) is a global health concern affecting men worldwide. Oxidative stress is believed to contribute to the initiation of early-stage PC lesions. Additionally, inflammation has long been acknowledged as a factor in the development of PC. We aimed to examine the biomarkers of oxidative stress and inflammation in PC patients before and after surgery. Patients and methods: A cross-sectional study was conducted at the Urology Outpatient Clinic of Bezmialem Vakif University Hospital. A total of 150 individuals were included in the study, divided into five groups: 50 Healthy controls, 25 patients with Benign Prostatic Hyperplasia (BPH), 25 patients with Low-Risk Prostate Cancer (LRPC), 25 patients with Medium-Risk Prostate Cancer (MRPC), and 25 patients with High-Risk Prostate Cancer (HRPC). Measurements of Total Oxidant Status (TOS), Total Antioxidant Status (TAS), Total Thiol (TT), and Native Thiol (NT) were performed using photometric methods. Oxidative Stress Index (OSI) and Disulfide (DIS) levels were calculated mathematically. Levels of Interleukin-10 (IL-10), Interleukin-1beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Presepsin were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Results: Compared to the healthy control group, the results indicated a statistically significant increase in both oxidative stress and inflammation levels. In the groups receiving both pharmaceutical therapy and surgical treatment (PC), a significant decrease in oxidative stress and inflammation levels was observed. Conclusion: Consequently, it is suggested that the assessment of oxidative stress and inflammatory biomarkers should be incorporated in the pre- and postoperative monitoring of patients with PC.